OMNIlife science and Global Orthopaedic Technology sign licensing deal


Monday, 10 April, 2017

OMNIlife science and Global Orthopaedic Technology have signed an exclusive licensing agreement for OMNI's APEX knee implants for Australia, New Zealand and South Africa.

The agreement will see Global Orthopaedic Technology acquire exclusive rights to manufacture, market and distribute the APEX knee implants in Australia, New Zealand and South Africa.

Global will continue to market OMNI's OMNIBotics robotic-assisted total knee and computer-assisted total hip replacement technology in the agreed markets under a separate distribution agreement. In addition, OMNI will continue to market Global's Paragon hip implants in the United States also under a separate distribution agreement.

"Licensing the knee implants to Global ensures the APEX Knee will continue to expand in the evidence-based Australian healthcare market and provide OMNI non-dilutive capital to support the demand for robotic-assisted total joint replacement products in the large US orthopedics market," said Rick Randall, OMNI CEO.

Related News

Proposed Australian trial eyes up blood testing for Alzheimer's

Utilising networks of GPs across three states, a large-scale study intends on combining digital...

Applications open for $300K pandemic therapeutics fellowships

Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...

CTA granted for CAR-T cell therapy for multiple myeloma

The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd